NasdaqCM:VTVTBiotechs
VTV Therapeutics (VTVT) Q1 Profit Swing To US$1.94 EPS Tests Bullish Narratives
vTv Therapeutics (VTVT) opened Q1 2026 with reported revenue of US$36.8 million and basic EPS of US$1.94, putting a spotlight on the shift in its income statement after a series of quarterly losses. Over the past year, the company has seen quarterly revenue move from effectively US$0 in early 2025 to US$36.8 million in Q1 2026, while basic EPS has swung from a loss of US$0.77 in Q1 2025 to a profit of US$1.94, indicating a sharp change in how much of each sales dollar is landing on the bottom...